Navigation Links
Cancer drugs may help treatment of schizophrenia
Date:7/20/2011

Researchers have revealed the molecular pathway that is affected during the onset of schizophrenia and successfully alleviated symptoms of the illness in mice, using a cancer drug currently in advanced clinical trials.

The research, published online in the journal Brain, is from a group led by Professor Peter Giese at King's College London, and offers new avenues for drug discovery.

Schizophrenia is one of the most common serious mental health conditions in the UK, and affects about 24 million people worldwide. The illness is a long-term mental health condition that causes a number of psychological symptoms, including hallucinations and delusions as well as behaviour changes. The exact cause of the illness is unknown, although it is generally believed to be a combination of genetic and environmental factors.

According to the World Health Organization, 90% of people with untreated schizophrenia are in developing countries. Current treatments for schizophrenia include both psychological treatments such as psychotherapy, counselling or cognitive behaviour therapy and/or medication. However, many of the antipsychotic drugs or major tranquillisers used to treat or manage the illness have very bad side-effects.

Professor Giese, based at the Institute of Psychiatry at King's, said: 'For the first time we have found that an enzyme activator called p35 is reduced in patients with schizophrenia and moreover, modelling this reduction in mice led to cognitive impairment typical for this disease. This gives us a better understanding of the changes that occur in the brain during the onset of schizophrenia.'

Proper brain development is ensured, in part, by the activation of a protein in the brain called Cdk5. The activation of Cdk5 requires the presence of an enzyme in the brain, called p35. The research found that in human post-mortem brains, there was approximately 50% less p35 in the brains of patients who had suffe
'/>"/>

Contact: Katherine Barnes
katherine.barnes@kcl.ac.uk
44-020-784-83076
King's College London
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Enhancing arrest of cell growth to treat cancer in mice
2. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
3. The National Coalition for Cancer Survivorship Joins the Commission on Cancer
4. Low forms of cyclin E reduce breast cancer drugs effectiveness
5. Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S.
6. Soft drinks may increase risk of pancreatic cancer
7. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
8. Genes Play Role in Prognosis With Non-Small Cell Lung Cancers
9. Single gene mutation induces endometrial cancer
10. Certain genetic profiles associated with recurrence-free survival for non-small cell lung cancer
11. Molecular pathways linked to sex, age affect outcomes in lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... April 28, 2015 2015 Market ... is a professional and in-depth research report. The ... application, industry overview, industry chain structure, international market ... covers the global (US, Europe, Japan, Asia) and ... macroeconomic environment & economic situation analysis. The Global ...
(Date:4/28/2015)... biologics safety testing market is growing at a favorable ... of the pharmaceutical and biological industries and an increasing ... number of drug approvals in North American countries has ... drug applications and Health Canada approved 99. In addition, ... pharmaceutical and 1,998 of the biotechnology patents granted in ...
(Date:4/28/2015)... Pittsburgh, PA (PRWEB) April 28, 2015 ... by Blair A. Jobe, MD, FACS , has ... replacing esophageal tissue with extracellular matrix (ECM) can help ... lethal form of esophageal cancer. , ECM is a ... for cell attachment and migration and signals that guide ...
(Date:4/28/2015)... 28, 2015 A first-in-human prostate ... Molecular Imaging and Biology showed initial safety, biodistribution, ... fluorine-18 labeled small-molecule PSMA inhibitor. The imaging biomarker ... Baltimore, MD by study co-author, Martin G. Pomper, ... of [18F]DCFPyL demonstrated a number of important findings. ...
(Date:4/28/2015)... 2015 The buyer power score for ... 5, indicating a medium level of buyer power in ... have equal power during negotiations. One factor helping buyer ... a health insurance policy from an insurance carrier (such ... can choose to self-fund their own policy or forgo ...
Breaking Medicine News(10 mins):Health News:Centrifuges Market 2015 Global Research Report 2Health News:Centrifuges Market 2015 Global Research Report 3Health News:Biological Safety Testing Market, By Application Product & Test – Global Forecast 2019 - Report Released by MarketsandMarkets 2Health News:Biological Safety Testing Market, By Application Product & Test – Global Forecast 2019 - Report Released by MarketsandMarkets 3Health News:Biological Safety Testing Market, By Application Product & Test – Global Forecast 2019 - Report Released by MarketsandMarkets 4Health News:Allegheny Health Network Launches First U.S. Clinical Trial of Extracellular Matrix as Replacement for Pre-Cancerous Tissue 2Health News:Allegheny Health Network Launches First U.S. Clinical Trial of Extracellular Matrix as Replacement for Pre-Cancerous Tissue 3Health News:Second Generation 18F-labeled Prostate-Specific Membrane Antigen (PSMA) Targeted Imaging Agent Found to be Highly Sensitive in Detecting Prostate Cancer 2Health News:Second Generation 18F-labeled Prostate-Specific Membrane Antigen (PSMA) Targeted Imaging Agent Found to be Highly Sensitive in Detecting Prostate Cancer 3Health News:New Data for Group Health Insurance Procurement Category Market Research Report from IBISWorld 2Health News:New Data for Group Health Insurance Procurement Category Market Research Report from IBISWorld 3Health News:New Data for Group Health Insurance Procurement Category Market Research Report from IBISWorld 4
... strain is similar to that seen in 1918, with ... 24 (HealthDay News) -- The 2009 H1N1 "swine flu" ... early in the 20th century, two teams of scientists ... people seemed to be less affected by H1N1 during ...
... Tuesday, President Obama signed into law U.S. health care ... affect them, their families, and businesses. The ... 2006 legislation in Massachusetts requiring all adults in the ... mandate. A new article from The Milbank Quarterly ...
... , ... Another Group Logic Solution to Their Product Portfolio , ... (PRWEB) March 24, 2010 -- Group Logic, the ... the United Kingdom, Jigsaw Systems, is adding the MassTransit product line to its solution ...
... ... solution will power health information exchange across LSU hospital system for more than 2800 ... ... will be able to access patient information across the 10 rural and metropolitan hospitals ...
... This release is available in Spanish . ... area as the original tumour remains the strongest, independent prognostic ... have been free of disease for a very long time, ... Breast Cancer Conference (EBCC7). Dr Sven Mieog, MD, a ...
... - Despite the aches and pains that occur in old ... positive experiences from their past. A new study, reported ... ( http://www.elsevier.com/locate/cortex ), reveals that older adults, ability to remember ... way in which the brain processes emotional content. In ...
Cached Medicine News:Health News:H1N1 Virus Yields Up More Secrets 2Health News:Massachusetts health care reform reviewed as a model for national plan 2Health News:Jigsaw Systems to Deliver Group Logic's MassTransit Solution for Managed File Transfer 2Health News:Carefx Portal Solution to Deliver First Time, Statewide Access to Patient Data Among Hospitals in the LSU Network 2Health News:Carefx Portal Solution to Deliver First Time, Statewide Access to Patient Data Among Hospitals in the LSU Network 3Health News:Carefx Portal Solution to Deliver First Time, Statewide Access to Patient Data Among Hospitals in the LSU Network 4Health News:Recurrence of breast cancer after more than 10 years is an important indicator of survival 2Health News:Recurrence of breast cancer after more than 10 years is an important indicator of survival 3Health News:Older adults remember the good times 2
(Date:4/28/2015)... 2015  Rosa & Co. LLC, a drug development ... today announced its pleasure to be lead partner for ... Systems Pharmacology (QSP). The conference focuses on uses and ... Logo - ... Rosa,s lead sponsorship is the second of ...
(Date:4/28/2015)... -- Boston Scientific Corporation (NYSE: BSX ) generated ... ended March 31, 2015, compared to the company,s ... $1.800 billion.  This represents 6 percent operational revenue ... flat revenue on a reported basis, all compared ... adjusted earnings per share of $0.21 for the ...
(Date:4/28/2015)... INDIANAPOLIS , April 28, 2015  People with ... receive a heart stent are prescribed an oral antiplatelet (OAP) ... blood clot in their heart stent (stent thrombosis), or even ... that 52 percent of 275 ACS patients who were currently ... they take their prescribed OAP therapy, even though most of ...
Breaking Medicine Technology:Rosa & Co. is the Lead Partner for the Quantitative Systems Pharmacology (QSP) Congress in Basel, Switzerland and Will Present the Keynote Address 2Rosa & Co. is the Lead Partner for the Quantitative Systems Pharmacology (QSP) Congress in Basel, Switzerland and Will Present the Keynote Address 3Boston Scientific Announces Results for First Quarter 2015 2Boston Scientific Announces Results for First Quarter 2015 3Boston Scientific Announces Results for First Quarter 2015 4Boston Scientific Announces Results for First Quarter 2015 5Boston Scientific Announces Results for First Quarter 2015 6Boston Scientific Announces Results for First Quarter 2015 7Boston Scientific Announces Results for First Quarter 2015 8Boston Scientific Announces Results for First Quarter 2015 9Boston Scientific Announces Results for First Quarter 2015 10Boston Scientific Announces Results for First Quarter 2015 11Boston Scientific Announces Results for First Quarter 2015 12Boston Scientific Announces Results for First Quarter 2015 13Boston Scientific Announces Results for First Quarter 2015 14Boston Scientific Announces Results for First Quarter 2015 15Boston Scientific Announces Results for First Quarter 2015 16Boston Scientific Announces Results for First Quarter 2015 17Boston Scientific Announces Results for First Quarter 2015 18Boston Scientific Announces Results for First Quarter 2015 19Boston Scientific Announces Results for First Quarter 2015 20Boston Scientific Announces Results for First Quarter 2015 21Boston Scientific Announces Results for First Quarter 2015 22Boston Scientific Announces Results for First Quarter 2015 23Boston Scientific Announces Results for First Quarter 2015 24Boston Scientific Announces Results for First Quarter 2015 25Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 2Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 3Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 4Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 5Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 6Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 7Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 8Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 9
... ... ... ... ...
... ... ... ... ...
Cached Medicine Technology:DATATRAK Attends 22nd Annual DIA EuroMeeting in Monaco 2DATATRAK Attends 22nd Annual DIA EuroMeeting in Monaco 3DATATRAK Attends 22nd Annual DIA EuroMeeting in Monaco 4DATATRAK Attends 22nd Annual DIA EuroMeeting in Monaco 5DATATRAK Attends 22nd Annual DIA EuroMeeting in Monaco 6HIMSS Honors Memorial Healthcare System for Using TheraDoc(TM) Decision Support Technology to Achieve 97 Percent Compliance With Pediatric Asthma Quality Measures 2HIMSS Honors Memorial Healthcare System for Using TheraDoc(TM) Decision Support Technology to Achieve 97 Percent Compliance With Pediatric Asthma Quality Measures 3HIMSS Honors Memorial Healthcare System for Using TheraDoc(TM) Decision Support Technology to Achieve 97 Percent Compliance With Pediatric Asthma Quality Measures 4HIMSS Honors Memorial Healthcare System for Using TheraDoc(TM) Decision Support Technology to Achieve 97 Percent Compliance With Pediatric Asthma Quality Measures 5HIMSS Honors Memorial Healthcare System for Using TheraDoc(TM) Decision Support Technology to Achieve 97 Percent Compliance With Pediatric Asthma Quality Measures 6HIMSS Honors Memorial Healthcare System for Using TheraDoc(TM) Decision Support Technology to Achieve 97 Percent Compliance With Pediatric Asthma Quality Measures 7
The under-patient design of the pediatric full access blanket warms even the tiniest patients while allowing full access for surgeons and staff....
Similar to Model 530, but just 37 inches long and with only one drape....
This pediatric blanket is a smaller version of the full body blanket, providing warmth to smaller patients during recovery....
2-ply material consisting of polyethylene film inner layer and non-woven outer layers....
Medicine Products: